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Abstract 
A novel series of 5-arylcarbamoyl- and 5-arylmethyl-2-methylisoxazolidin-3-yl-3-
phosphonates have been synthesized via cycloaddition of N-methyl-C-
(diethoxyphosphoryl)nitrone with N-substituted naphthalimide acrylamides and N-
allylnaphthalimides. All cis- and trans-isoxazolidine phosphonates obtained herein were 
assessed for antiviral activity against a broad range of DNA and RNA viruses. Isoxazolidines 
trans-9d and trans-9f exhibited the highest activity (EC50 = 8.9 μM) toward cytomegalovirus. 
Compounds cis- and trans-9d as well as cis- and trans-9f were found potent against HSV and 
Vaccinia viruses (EC50 in the 45–58 μM range), whereas isoxazolidines 10a and 10d 
suppressed replication of Coxsackie B4 and Punta Toro viruses (EC50 in the 45–73 μM 
range). Antiproliferative evaluation of all obtained isoxazolidines revealed the promising 
activity of cis-9b, cis-9d, trans-9d, cis-9e, trans-9e, cis-9f and trans-9f toward tested cancer 
cell lines with IC50 in the 1.1–12 μM range. 
 
Introduction 
Despite significant achievements in cancer chemotherapy a search for more selective 
compounds with capability to better differentiate malignant tumors from normal cells and able 
to minimize side effects of current drugs continues. Taking into account their mechanisms of 
action, therapeutic agents belong to different pharmacological classes. Among them, those 
which interact with DNA, such as DNA alkylating agents, intercalators or groove binders, are 
of special interest.1–3 Intercalators constitute a well explored class of compounds because their 
mode of action is the most predictable and relies on inhibition of replication process by 
reversible binding to DNA.4,5 The planar aromatic fragments of intercalators insert into the 
DNA double helix, thereby distorting the DNA backbone conformation and poison the DNA 
topoisomerases I or II.6 Several factors are responsible for stabilization a drug–DNA complex, 
namely stacking π-bond interactions, van der Waals forces and eventually hydrogen bonding 
between the aromatic fragment of a drug moiety and the purine/pyrimidine bases present in 
DNA strains. Intercalators can be classified according to their aromatic/heteroaromatic 
subunit or electrostatic potential they posses.2,3 Among them, naphthalimide derivatives have 
been found promising as anticancer agents since they are able to intercalate into DNA and 
some of them, including amonafide 17,8 and mitonafide 2,9 have reached clinical trials for 
treatment of solid tumors, however most of them showed poor therapeutic indices. 
On the other hand, various functional groups present in the structure of intercalators may also 
contribute to the binding of a drug to DNA. The amino group of a sugar residue in 
doxorubicin 3 forms an ionic bond with the phosphate function of the DNA which results in 
additional and very efficient stabilization of locking the drug into an active site.10 There are 
also known groups of intercalators which activities are related to the specific shape of 
molecule rather than their aromatic ring system. Studies on intercalating properties of 2-
[(arylmethyl)amino]-2-methyl-1,3-propanodiols (AMAPs) 4 proved that the amino side chain 
is responsible for DNA binding due to electrostatic interactions and enhanced activity which 
was observed for derivatives with 2-amino-1,3-propanediol moiety.11,12 
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Figure 1. Structures of known intercalators 
 
Compounds 5 (Fig 2) have been designed as new isoxazolidine-containing intercalators 
equipped with planar polycyclic aromatic frameworks at C3 and their cytotoxic and apoptotic 
properties have already been described.13,14 Recently, we succeeded in the preparation of 
compounds 6 having 1- and 2-naphthyl substituents at C5 of an isoxazolidine ring and they 
proved cytotoxic against HeLa and K562 cell lines with IC50 values 50 and 90 μM, 
respectively.15 Moreover, isoxazolidines 7 containing at C5 a carbamoyl linker which 
separates the isoxazolidine ring and substituted phenyls suppressed divisions of three cancer 
cell lines at concentrations ranging from 228 to 102 μM.16 
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Figure 2. Biologically active isoxazolidines 
 
Herein, a new series of 5-arylcarbamoyl- and 5-arylmethylisoxazolidines substituted at C3 
with a dialkoxyphosphoryl functionality 9 and 10 have been designed as a continuation of an 
ongoing project directed towards the construction of compounds with antineoplastic activity 
based on application of the phosphoryl nitrone 8 (Scheme 1). 
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Scheme 1. Retrosynthesis of (isoxazolidinyl)phosphonates 9 and 10. 
Our approach to the synthesis of phosphonylated intercalators relies on assumption that the 
designed molecules contain both aromatic systems able to intercalate into DNA and the 
diethoxyphosphoryl function at C3 of the isoxazolidine ring which could be further 
phosphorylated but also contains a non-hydrolysable C–P bond.17 
 
 
Results and Discussion 
 
To the best of our knowledge all acrylamides 11 as well as allylated naphthalimides 12, 
except for 12a and 12b have not been described in the literature. For the purpose of this study, 
N-substituted acrylamides 11 were synthesized starting from commercially available 
naphthalic anhydride 13 via multistep procedures including nitration18 followed by a standard 
reduction of the nitro group,19 transformation of the aminoanhydride 15 into naphthalimides 
16a-f by treatment with alkyl amines or ethylenediamines20 and finally preparation of 
acrylamides 11a–f from 16a–f and acryloyl chloride in the presence of triethylamine (Scheme 
2). The series of dipolarophiles 12a–c were obtained in the reaction of naphthalic anhydrides 
13, 14 and 15 with allylamine.20 Furthermore, naphthalimide 12c was converted into its acetyl 
derivative 12d.21 
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Scheme 2. Reaction conditions: a) H2SO4, HNO3; b) SnCl2, HCl; c) R′NH2, EtOH, see Table 
1; d) acryloyl chloride, NEt3, see Table 1; e) allylamine, EtOH; f) Ac2O. 
 
1,3-Dipolar cycloadditions of a nitrone 822 with naphthalimides 11a–f were performed in 
toluene or a toluene–chloroform mixture at 70°C and led to the formation of 
diastereoisomeric mixtures of (3-diethoxyphosphoryl)isoxazolidines trans-9a–f and cis-9a–f 
(Scheme 3; Table 1). In all cases moderate trans/cis diastereoselectivities were observed with 
trans-isomers 9a–f predominating (de 56–72%). Purification of the crude mixtures of 
cycloadducts on silica gel columns resulted in separation of all major diastereoisomers trans-
9a-f as well as all minor isomers cis-9a-f. 
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Scheme 3. Reaction conditions: toluene or toluene–chloroform, 70°C 
Table 1. Isoxazolidines trans-9 and cis-9 obtained according to Scheme 3 
Entry 
Acrylamide 11 Ratio of 
trans-9:cis-9 
Yield (%) 
R 
a  81:19 trans-9a (63)a + cis-9a (11)a + trans-9a and cis-9a (11)b 
b  84:16 trans-9b (71)a + cis-9b (14)a + trans-9b and cis-9b (2)b 
c 
 
79:21 trans-9c (67)a + cis-9c (19)a + trans-9c and cis-9c (5)b 
d N
 
79:21 trans-9d (33)a + cis-9d (8)a + trans-9d and cis-9d (52)b 
e N
 
86:14 trans-9e (32)a + cis-9e (11)a + trans-9e and cis-9e (54)b 
f N
 
78:22 trans-9f (31)a + cis-9f (8)a + trans-9f and cis-9f (50)b 
a yield of pure isomer, 
b yield of pure mixture of cis- and trans-isomers. 
 
Reactions of a nitrone 8 with N-allylated naphthalimides 12a–d were carried out in toluene or 
toluene–chloroform solutions at 70°C and gave mixtures of isomeric isoxazolidines trans-
10a–d and cis-10a–d with good trans/cis diastereoselectivities (de 72–82%). Crude mixtures 
of cycloadducts were subjected to purification on silica gel columns and subsequent 
crystallization. However, attempts at separating diastereoisomers trans-10a-d and cis-10a-d 
failed leading to mixtures enriched in isomers trans-10 (Scheme 4; Table 2). 
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Scheme 4. Reaction conditions: toluene or toluene–chloroform, 70°C 
Table 2. Isoxazolidines trans-10 and cis-10 obtained according to Scheme 4 
Entry 
Imide 9 Ratio of 
trans-10:cis-10 
Yield (%)a 
R 
a H 91:9 trans-10a and cis-10a (76%; trans-10a:cis-10a = 93:7) 
b NO2 91:9 trans-10b and cis-10b (67%; trans-10b:cis-10b = 94:6) 
c NH2 86:14 trans-10c and cis-10c (32%; trans-10c:cis-10c = 93:7) 
d NHC(O)CH3 88:12 trans-10d and cis-10d (73%; trans-10d:cis-10d = 93:7) 
a yield of pure mixture of cis- and trans-isomers 
 
The relative configurations of the isoxazolidines trans-9a–f and cis-9a–f were determined 
taking advantage of our previous studies on stereochemistry of cycloaddition of N-methyl-C-
diethoxyphosphorylnitrone 8 with (hetero)arylacrylamides16 since similar 1H NMR spectral 
patterns for the respective series of isoxazolidines trans-9a–f and cis-9a–f were observed as 
compared to the previously described trans- and cis-5-(hetero)arylcarbamoyl-2-
methylisoxazolidin-3-yl-3-phosphonates.16,23 Briefly, for the major trans-isomers 9a–f the 3E 
conformation (Figure 3) of an isoxazolidine ring was established taking advantage of the 
diagnostic values of vicinal coupling constants [JCCCP = 7.7–8.9 Hz, JH3–H4α = 8.1–8.3 Hz, JH3–
H4β = 8.5–8.9 Hz, JH4α–P = 9.4–10.3 Hz, JH4β–P = 15.7–16.1 Hz, JH4α–H5 = 5.5–5.8 Hz and JH4β–
H5 = 8.7–8.9 Hz] extracted from the respective 1H and 13C NMR spectra. In this conformation 
the diethoxyphosphoryl group resides in the equatorial position of the isoxazolidine ring while 
carbamoyl substituents are located pseudoequatorially. Similarly, relative configurations of 
isoxazolidines trans-10a–d and cis-10a–d were established based on very close 
stereochemical outcomes found for the reaction between a nitrone 8 and N-allylated 
naphthalimides 12a–d as compared with already elaborated analogous reactions of a nitrone 8 
and N-allylated nucleobases.24 
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Figure 3. The 3E conformation of an isoxazolidine ring in trans-9a–f. 
 
Antiviral activity 
Pure 5-arylcarbamoyl-2-methylisoxazolidin-3-yl-3-phosphonates trans-9a–f and cis-9a–f and 
inseparable mixtures of 5-arylmethyl-2-methylisoxazolidin-3-yl-3-phosphonates trans-10a–
d/cis-10a–d were evaluated for inhibitory activity against a wide variety of DNA and RNA 
viruses, using the following cell-based assays: (a) human embryonic lung (HEL) cells: herpes 
simplex virus-1 (KOS), herpes simplex virus-2 (G), thymidine kinase deficient (acyclovir 
resistant) herpes simplex virus-1 (TK- KOS ACVr), vaccinia virus, vesicular stomatitis virus 
and, adenovirus-2, cytomegalovirus (AD-169 strain and Davis strain), varicella-zoster virus 
(TK+ VZV strain and TK- VZV strain); (b) HeLa cell cultures: vesicular stomatitis virus, 
Coxsackie virus B4 and respiratory syncytial virus; (c) Vero cell cultures: para-influenza-3 
virus, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus; (d) MDCK cell 
cultures: influenza A virus (H1N1 and H3N2 subtypes) and influenza B virus and (e) CrFK 
cell cultures: feline herpes virus (FHV) and feline corona virus (FIPV). Ganciclovir, 
cidofovir, acyclovir, brivudin, (S)-9-(2,3-dihydroxypropyl)adenine [(S)-DHPA], oseltamivir 
carboxylate, amantadine, rimantadine, ribavirin, dextran sulfate (molecular weight 5000, DS-
5000), Hippeastrum hybrid agglutinin (HHA) and Urtica dioica agglutinin (UDA) were used 
as the reference compounds. The antiviral activity was expressed as the EC50: the compound 
concentration required to reduce virus plaque formation (VZV) by 50% or to reduce virus-
induced cytopathogenicity by 50% (other viruses).  
 
Some compounds of the series of isoxazolidines cis-9/trans-9 were found active against 
cytomegalovirus with activities below 60 μM (Table 3). Among these compounds, trans-9d (EC50 
= 8.9 μM) and trans-9f (EC50 = 8.9 μM – 20 µM) exhibited the highest activity with EC50 values 
values comparable to those found for the reference compound ganciclovir.  Among the series of 
isoxazolidines cis-9/trans-9, some of the derivatives were also able to slightly inhibit VZV 
replication with EC50 values in the range of 20-45 µM (Table 4). On the over hand, none of the 
compounds from the series trans-10/cis-10 was found active either towards HCMV or against VZV. 
 
Table 3. Cytotoxicity and antiviral activity against cytomegalovirus in HEL cell cultures 
Compound R 
Antiviral activity EC50 (μM)a Cytotoxicity (μM) 
AD-169 strain Davis strain Cell morphology MCCb 
cis-9a 
 
 
   
(exp. 1) 
(exp. 2) 
45 
45 
45 
45 
>100 
>100 
trans-9a    
(exp. 1) 
(exp. 2) 
>20 
49 
55 
45 
>100 
>100 
cis-9b 
 
   
(exp. 1) 
(exp. 2) 
>20 
>20 
>20 
>20 
100 
100 
trans-9b    
(exp. 1) 
(exp. 2) 
>20 
>20 
>20 
>20 
100 
100 
cis-9c 
 
   
(exp. 1) 
(exp. 2) 
45 
45 
45 
45 
>100 
>100 
trans-9c 
(exp. 1) 
(exp. 2) 
   
>100 
>100 
>100 
>100 
>100 
>100 
cis-9d 
N
 
   
(exp. 1) 45 41 >100 
(exp. 2)  37 37 >100 
trans-9d    
(exp. 1) 
(exp. 2) 
8.9 
8.9 
8.9 
8.9 
100 
100 
cis-9e 
N
 
   
(exp. 1) 
(exp. 2) 
100 
100 
100 
>100 
>100 
>100 
trans-9e    
(exp. 1) 
(exp. 2) 
55 
55 
49 
63 
>100 
>100 
cis-9f 
N
 
   
(exp. 1) 
(exp. 2) 
45 
45 
45 
45 
>100 
>100 
trans-9f    
(exp. 1) 
(exp. 2) 
8.9 
10.9 
10.9 
20 
100 
100 
Cidofovir 
(exp. 1) 
(exp. 2) 
  
0.92 
0.92 
 
1.02 
1.14 
 
>350 
>350 
Ganciclovir 
(exp. 1) 
(exp. 2) 
  
7.1 
6.3 
 
7.1 
7.9 
 
>350 
>350 
a effective concentration required to reduce virus plaque formation by 50%. Virus input was 100 plaque forming units (PFU), 
b minimum cytotoxic concentration that causes a microscopically detectable alternation of cell morphology, 
c cytotoxic concentration required to reduce cell growth by 50 % 
 
Table 4. Cytotoxicity and antiviral activity against varicella-zoster virus (VZV) in HEL cell 
cultures 
Compound R 
Antiviral activity EC50 (μM)a Cytotoxicity (μM) 
TK+ VZV strain TK– VZV strain Cell morphology MCCb 
cis-9a 
 
 
   
(exp. 1) 
(exp. 2) 
20 
32 
38 
45 
>100 
>100 
trans-9a    
(exp. 1) 
(exp. 2) 
32 
28 
40 
41 
>100 
>100 
cis-9b 
 
   
(exp. 1) 
(exp. 2) 
20 
32 
38 
45 
>100 
>100 
trans-9b    
(exp. 1) 
(exp. 2) 
32 
28 
40 
41 
>100 
>100 
cis-9c 
 
   
(exp. 1) 
(exp. 2) 
45 
45 
45 
45 
>100 
>100 
trans-9c 
(exp. 1) 
(exp. 2) 
   
>100 
>100 
>100 
>100 
>100 
>100 
cis-9d 
N
 
 
   
(exp. 1) 
(exp. 2) 
>20 
11 
20 
20 
100 
100 
trans-9d    
(exp. 1) 
(exp. 2) 
14 
15 
26 
34 
>100 
>100 
cis-9e 
N
 
   
(exp. 1) 
(exp. 2) 
>20 
41 
36 
44 
>100 
>100 
trans-9e    
(exp. 1) 
(exp. 2) 
30 
>20 
32 
>20 
100 
100 
cis-9f 
N
 
   
(exp. 1) 
(exp. 2) 
>20 
>20 
>20 
79 
100 
>100 
trans-9f    
(exp. 1) 
(exp. 2) 
>20 
>20 
>20 
>20 
100 
100 
Acyclovir 
(exp. 1) 
(exp. 2) 
  
3.6 
1.5 
 
44 
33 
 
>440 
>440 
Brivudin 
(exp. 1) 
(exp. 2) 
  
0.042 
0.029 
 
1.0 
4.9 
 
>300 
>300 
a effective concentration required to reduce virus plaque formation by 50%. Virus input was 100 plaque forming units (PFU), 
b minimum cytotoxic concentration that causes a microscopically detectable alternation of cell morphology, 
c cytotoxic concentration required to reduce cell growth by 50 % 
 
 
Furthermore, the isoxazolidine derivatives equipped with N,N-dimethylaminoethyl (trans-9d 
and cis-9d) and 2-(pirolidyn-1-yl)ethyl (trans-9f and cis-9f) functions were found slightly 
active against three strains of herpex simplex virus (except for cis-9f) and vaccinia virus with 
EC50 values ranging from 45 μM to 100 μM (Table 5). Moreover, these compounds were not 
cytotoxic toward HEL cells (in which the viruses were replicated) at concentrations up to 100 
µM or displayed a minimum cytotoxic concentration (MCC) of 100 µM.  
 
 
Table 5. Cytotoxicity and antiviral activity in HEL cell cultures 
Compound R 
MCCa 
(μM) 
EC50b (μM) 
HSV-1 
(KOS) 
HSV-1 (TKˉ 
KOS ACVr) 
HSV-2 (G) Vaccinia 
virus 
trans-9d 
N
 
 
     
(exp. 1) 
(exp. 2) 
≥100 
≥100 
45 
45 
45 
45 
45 
>100 
45 
>100 
cis-9d      
(exp. 1) 
(exp. 2) 
>100 
>100 
50 
58 
50 
58 
50 
58 
45 
>100 
trans-9f 
N
 
     
(exp. 1) 
(exp. 2) 
≥100 
≥100 
45 
45 
45 
45 
45 
>100 
45 
>100 
cis-9f      
(exp. 1) 
(exp. 2) 
>100 
>100 
>100 
>100 
>100 
>100 
58 
100 
50 
58 
Brivudin 
(exp. 1) 
(exp. 2) 
  
>250 
>250 
 
0.01 
0.05 
 
2.0 
10 
 
146 
250 
 
17 
22 
Cidofovir 
(exp. 1) 
(exp. 2) 
  
>250 
>250 
 
1.0 
2.0 
 
1.2 
2.0 
 
1.0 
1.5 
 
22 
22 
Acyclovir 
(exp. 1) 
(exp. 2) 
  
>250 
>250 
 
0.2 
0.2 
 
2.0 
2.0 
 
0.08 
0.2 
 
>250 
>250 
Ganciclovir 
(exp. 1) 
(exp. 2) 
  
>100 
>100 
 
0.03 
0.02 
 
0.8 
0.5 
 
0.03 
0.03 
 
>100 
>100 
a minimum cytotoxic concentration that causes a microscopically detectable alternation of cell morphology, 
b effective concentration that is required to reduce virus-induced cytopathogenicity by 50 % 
 
In the second series of isoxazolidines trans-10 and cis-10 phosphonates, trans-10a/cis-10a 
and trans-10d/cis-10d inhibited the replication of Coxsackie virus B4 at concentrations 45–
100 μM while only  trans-10d/cis-10d showed a weak activity against Punta Toro virus (Table 
6). These compounds did not alter morphology of Vero cells where the antiviral assays were 
performed. 
The cytotoxicity of the tested compounds toward the uninfected host cells was defined as the 
minimum compound concentration (MCC) that caused a microscopically detectable alteration 
of normal cell morphology. None of the tested compounds affected cell morphology of HEL, 
HeLa and Vero cells at concentrations up to 100 μM. 
None of the isoxazolidines cis-9/trans-9 and trans-10 and cis-10 phosphonates showed 
activity against the other tested viruses, including adenovirus-2, vesicular stomatitis virus, 
respiratory syncytial virus, para-influenza-3 virus, reovirus-1, Sindbis virus, influenza A and 
B viruses, feline herpes virus, and feline corona virus. 
 
 
Table 6. Cytotoxicity and antiviral activity in Vero cell cultures. 
Compound R MCCa (μM) EC50b (μM) 
Coxsackie virus 
B4 
Punta Toro 
virus 
trans-10a/cis-10a (93:7) 
H 
   
(exp. 1) 
(exp. 2) 
>100 
>100 
45 
73 
>100 
>100 
trans-10d/cis-10d (93:7) 
NHC(O)CH3 
   
(exp. 1) 
(exp. 2) 
>100 
>100 
45 
58 
50 
100 
DS-10.000 (μg/ml) 
(exp. 1) 
(exp. 2) 
  
>100 
>100 
 
>100 
>100 
 
45 
100 
Ribavirin 
(exp. 1) 
(exp. 2) 
  
>250 
>250 
 
>250 
>250 
 
112 
250 
a minimum cytotoxic concentration that causes a microscopically detectable alternation of cell morphology, 
b effective concentration that is required to reduce virus-induced cytopathogenicity by 50 % 
 
 
Cytostatic activity 
 
The 50% cytostatic inhibitory concentration (IC50) causing a 50% decrease in cell 
proliferation was determined against murine leukemia L1210, human lymphocyte CEM and 
human cervix carcinoma HeLa cells. The synthesized compounds showed differences in their 
antiproliferative activity with IC50 ranging from 1.1 to 180 μM (Table 7). Among 
isoxazolidines having a carbamoyl linker, structure–activity relationship studies indicated that 
the presence of a tertiary nitrogen atom in a side chain significantly increased cytostatic 
activity of the tested compounds. Phosphonates trans-9a–c and cis-9a–c having straight 
aliphatic chains (propyl, butyl and isobutyl) were considerably less cytostatic than those 
containing tertiary amino functions, namely trans-9d–f and cis-9d–f. Nevertheless, trans-9a–
c and cis-9a–c were able to inhibit proliferation of the tested cell lines at concentrations below 
86 μM (IC50). Moreover, compounds trans-9a and cis-9c decreased viability of the MDCK 
cell line at concentrations of 46.2 and 51.8 μM (CC50), respectively. Furthermore, both trans- 
and cis-isoxazolidines 9d, 9e and 9f having aminoalkyl substituents appeared to be the most 
cytostatic towards L1210, CEM and HeLa cell lines with IC50’s below 23 μM. Among them, 
trans-9d and cis-9d, which can be considered as amonafide analogues, as well as trans-9f and 
trans-9f proved highly cytostatic toward murine leukemia L1210 and human cervix 
carcinoma HeLa cells (IC50 = 1.1–3.3 μM). Besides their high cytostatic activity, compounds 
trans-9d, cis-9d, trans-9f and cis-9f were found to reduce viability of MDCK and CrFK cells 
at concentrations in the range of 95.2–62.2 μM (CC50). In addition, phosphonates trans-9a, 
trans-9b, cis-9b, cis-9c, trans-9e and cis-9e exhibited high cytostatic activity against human 
lymphocyte cells (CEM), comparable to that of 5-fluorouracil, while trans-9d and trans-9f 
were even five-fold more cytostatic than 5-fluorouracyl. Furthermore, although no correlation 
between configuration of isoxazolidines trans-9a–c/cis-9a–c and trans-9e/cis-9e and their 
biological activity was observed, trans-configured isoxazolidines trans-9d and trans-9f were 
found two-fold more cytostatic than the corresponding cis-isomers cis-9d and cis-9f. 
 
The second series of 5-arylmethyl-2-methylisoxazolidin-3-yl-3-phosphonates trans-10/cis-10 
also showed significant cytostatic activity against all three tested cancer cell lines (IC50 from 
20 to 180 μM). Isoxazolidines trans-10b/cis-10b substituted with the nitro group at C5 of a 
naphthalimide unit emerged as the most cytostatic with the highest potency toward HeLa cell 
line (IC50 = 20 μM). None of the evaluated compounds trans-10/cis-10 decreased viability of 
MDCK and CrFK cells at concentration up to 100 μM. 
 
Table 7. Inhibitory effect of the tested compounds against the proliferation of murine 
leukemia (L1210), human T-lymphocyte (CEM) and human cervix carcinoma cells (HeLa). 
Compound R 
 IC50a (μM)   CC50b (μM) 
L1210 CEM HeLa  MDCK CrFK 
cis-9a 
 
76 ± 16 47 ± 18 70 ± 41  >100 >100 
trans-9a 41 ± 7 28 ± 4 74 ± 11  46.2 >100 
cis-9b 
 
28 ± 7 19 ± 1 25 ± 3  >100 >100 
trans-9b 85 ± 54 25 ± 7 78 ± 3  >100 >100 
cis-9c 
 
73 ± 27 26 ± 3 49 ± 21  51.8 >100 
trans-9c 72 ± 52 48 ± 10 56 ± 27  >100 >100 
cis-9d 
N
 
2.9 ± 0.2 6.0 ± 1.1 3.3 ± 0.3  >100 62.2 
trans-9d 1.5 ± 0.3 3.4 ± 0.4 1.8 ± 0.9  75.2 95.2 
cis-9e 
N
 
16 ± 4 23 ± 0 7.3 ± 2.4  >100 >100 
trans-9e 11 ± 0 21 ± 1 13 ± 5  >100 >100 
cis-9f 
N
 
4.4 ± 0.1 12 ± 1 3.0 ± 0.6  >100 89.1 
trans-9f 1.7 ± 0.4 3.9 ± 0.0 1.1 ± 0.0  87.3 >100 
trans-10a/cis-10a 
(93:7) 
H 180 ± 47 111 ± 14 77 ± 20  >100 >100 
trans-10b/cis-10b 
(94:6) 
NO2 34 ± 6 51 ± 6 20 ± 3  >100 >100 
trans-10c/cis-10c 
(93:7) 
NH2 95 ± 42 99 ± 2 101 ± 58  >100 >100 
trans-10d/cis-10d 
(93:7) 
NHC(O)CH3 136 ± 14 125 ± 4 111 ± 3  >100 >100 
5-Fluorouracil  0.33 ± 0.17 18 ± 5 0.54 ± 0.12  ― ― 
a 50% Inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%, 
b 50% Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-
based MTS assay. 
 
Conclusions 
Two new series of 5-arylcarbamoyl-2-methylisoxazolidin-3-yl-3-phosphonates trans-9 and 
cis-9 and 5-arylmethyl-2-methylisoxazolidin-3-yl-3-phosphonates trans-10 and cis-10 have 
been obtained from N-methyl-C-diethoxyphosphorylnitrone 8 and the respective N-
substituted naphthalimide acrylamides or N-allylated naphthalimides via the 1,3-dipolar 
cycloaddition. 
All synthesized isoxazolidine phosphonates trans-9 and cis-9 as well as the respective 
mixtures of trans-10/cis-10 were evaluated against a variety of DNA and RNA viruses. 
Several of these derivatives showed some activity against varicella-zoster virus and 
cytomegalovirus. Among all tested compounds, isoxazolidines trans-9d and trans-9f exhibited 
the highest activity (EC50 = 8.9 μM) toward cytomegalovirus.  Some of the tested compounds 
were also endowed with antiviral activity against HSV and Vaccinia (cis- and trans-9d, cis- 
and trans-9f, EC50 in the 45–58 μM range), Coxsackie B4 and Punta Toro (10a and 10d, EC50 
in the 45–73 μM range) viruses. Cytostatic activity of trans-9, cis-9 and trans-10/cis-10 was 
evaluated on L1210, CEM and HeLa cell lines and for the most cystostatic compounds (cis-
9b, cis-9d, trans-9d, cis-9e, trans-9e, cis-9f and trans-9f), IC50 values were found in the 1.1–
12 μM range. Generally, compounds with a carbamoyl linker trans-9/cis-9 were more active 
than trans-10/cis-10 having a methylene bridge. 
 
 
 
Experimental Section 
 
1H NMR spectra were taken in CDCl3 on the following spectrometers: Varian Mercury-300 
and Bruker Avance III (600 MHz) with TMS as internal standard. 13C NMR spectra were 
recorded for CDCl3 solution on the Varian Mercur-300 machine at 75.5 MHz, while for 
DMSO solution on Bruker Avance III at 151.0 MHz. 31P NMR spectra were performed in 
CDCl3 solution on the Varian Mercury-300 at 121.5 MHz or on Bruker Avance III at 243.0 
MHz. 
IR spectra were measured on an Infinity MI-60 FT-IR spectrometer. Melting points were 
determined on Boetius apparatus and are uncorrected. Elemental analyses were performed by 
the Microanalytical Laboratory of this Faculty on Perkin-Elmer PE 2400 CHNS analyzer. 
The following adsorbents were used: column chromatography, Merck silica gel 60 (70–230 
mesh); analytical TLC, Merck TLC plastic sheets silica gel 60 F254. 
 
General procedure for the preparation of 1,8-naphthalimides 16a-f and 12a-c 
A suspension of 1,8-naphthalic anhydride 13, 14 or 15 (1.00 mmol), appropriate aliphatic 
amine, substituted ethylenediamine or allylamine (2.00 mmol) in ethanol (10 mL) was heated 
under reflux for 3 h. After evaporation of a solvent under reduced pressure the crude product 
was purified on a silica gel column with chloroform:methanol mixtures (100:1, 50:1 v/v) to 
give the corresponding 1,8-naphthalimides 16a-f and 12a-c. 
N OO
NH2  
N-propyl-3-amino-1,8-naphthalimide 16a 
Yield: 74%; yellow amorphous solid (crystallized from chloroform/hexane) mp 202–203°C; 
IR (KBr, cm-1) νmax: 3473, 3368, 1688, 1646, 1580, 1341, 1308, 1220, 778, 744; 1H NMR 
(300 MHz, CDCl3) δ: 8.31 (dd, 1H, J = 7.3, 1.1 Hz), 8.02 (d, 1H, J = 2.3 Hz), 7.92 (dd, 1H, J 
= 8.3, 1.1 Hz), 7.60 (dd, 1H, J = 8.3, 7.3 Hz), 7.30 (d, 1H, J = 2.3 Hz), 4.18 (br s, 2H, NH2), 
4.13 (d, 2H, J = 7.5 Hz, CH2CH2CH3), 1.81‒1.69 (m, 2H, CH2CH2CH3), 1.01 (d, 3H, J =7.5 
Hz, CH2CH2CH3); 13C NMR (75.5 MHz, CDCl3) δ: 164.51 (s, C(O)), 164.28 (s, C(O)), 
145.33, 133.50, 131.71, 127.54, 127.30, 123.79, 122.67, 122.62, 122.11, 114.05, 42.18 (s, 
CH2CH2CH3), 21.71 (s, CH2CH2CH3), 11.85 (s, CH2CH2CH3); Anal. Calcd. for C15H14N2O2: 
C, 70.85; H, 5.55; N, 11.02; found: C, 70.61; H, 5.70; N, 10.77. 
N OO
NH2  
N-isobutyl-3-amino-1,8-naphthalimide 16c 
Yield: 77%; yellow amorphous solid (crystallized from chloroform/hexane) mp 185–186°C; 
IR (KBr, cm-1) νmax: 3452, 3357, 1692, 1657, 1627, 1581, 1447, 1343, 1297, 1222, 1072, 783; 
1H NMR (300 MHz, CDCl3) δ: 8.33 (dd, 1H, J = 7.3, 1.0 Hz), 8.03 (d, 1H, J = 2.4 Hz), 7.93 
(dd, 1H, J = 8.3, 1.0 Hz), 7.60 (dd, 1H, J = 8.3, 7.3 Hz), 7.31 (d, 1H, J = 2.4 Hz), 4.15 (br s, 
2H, NH2), 4.03 (d, 2H, J = 7.3 Hz, CH2CH(CH3)2), 2.28‒2.18 (m, 1H, CH2CH(CH3)2), 0.98 
(d, 6H, J = 6.7 Hz, CH2CH(CH3)2); 13C NMR (75.5 MHz, CDCl3) δ: 164.79 (s, C(O)), 164.57 
(s, C(O)), 145.33, 133.50, 131.67, 127.61, 127.31, 123.75, 122.72, 122.59, 122.21, 114.05, 
47.40 (s, CH2CH(CH3)2), 27.69 (s, CH2CH(CH3)2), 20.62 (s, CH2CH(CH3)2); Anal. Calcd. for 
C16H16N2O2: C, 71.62; H, 6.01; N, 10.44; found: C, 71.42; H, 5.84; N, 10.19. 
N OO
NH2  
N-(2-propenyl)-3-amino-1,8-naphtalimide 12c 
Yield: 92%; orange amorphous solid mp 221–222°C; IR (KBr, cm-1) νmax: 3455, 3364, 1688, 
1644, 1615, 1578, 1448, 1379, 1330, 1237, 1180, 777, 744; 1H NMR (300 MHz, CDCl3) δ: 
8.32 (dd, 1H, J = 7.3, 1.0 Hz), 8.03 (d, 1H, J = 2.4 Hz), 7.93 (dd, 1H, J = 8.1, 1.0 Hz), 7.60 
(dd, 1H, J = 8.1, 7.3 Hz), 7.30 (d, 1H, J = 2.4 Hz), 5.99 (ddt, 1H, J = 17.0, 10.3, 5.7 Hz, 
CH2CH=CH2), 5.31 (dq, 1H, J = 17.0, 1.3 Hz, CH2CH=CH2), 5.20 (dq, 1H, J = 10.3, 1.3 Hz, 
CH2CH=CH2), 4.79 (dt, 2H, J = 5.7, 1.3 Hz, CH2CH=CH2), 4.17 (br s, 2H, NH2); 13C NMR 
(151.0 MHz, DMSO) δ: 163.92 (s, C(O)), 163.75 (s, C(O)), 148.35, 134.05, 133.46, 132.03, 
127.39, 125.96, 122.93, 122.26, 122.13, 121.11, 116.65, 112.35, 42.08 (s, CH2CH=CH2). 
Anal. Calcd. for C15H12N2O2: C, 71.42; H, 4.79; N, 11.10; found: C, 71.14; H, 4.88; N, 10.96. 
N OO
N
H
O
 
N-(2-propenyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)acetamide 12d 
N-(2-propenyl)-3-amino-1,8-naphthalimide 12c (1.00 mmol) was treated with acetic 
anhydride (3.00 mL, 31.55 mmol) and stirred for 5 h at room temperature. The reaction 
mixture was cooled to room temperature and cold water (10 mL) was added. Yellow 
precipitate was filtered off, washed several times with water and dried to afford naphthalimide 
12d. Yield: 86%; yellow amorphous solid mp 253–254°C; IR (KBr, cm-1) νmax: 3291, 3213, 
1703, 1663, 1630, 1565, 1465, 1424, 1335, 1264, 1236, 1180, 880, 783, 745; 1H NMR (300 
MHz, CDCl3) δ: 8.95 (s, 1H), 8.50 (d, 1H, J = 7.1 Hz), 8.27 (d, 1H, J = 2.2 Hz), 8.18 (d, 1H, J 
= 8.3 Hz), 7.73 (dd, 1H, J = 8.3, 7.1 Hz), 7.69 (br s, 1H, NH), 5.98 (ddt, 1H, J = 17.1, 10.5, 
5.5 Hz, CH2CH=CH2), 5.31 (d, 1H, J = 17.1 Hz, CH2CH=CH2), 5.21 (d, 1H, J = 10.5 Hz, 
CH2CH=CH2), 4.80 (d, 2H, J = 5.5 Hz, CH2CH=CH2), 2.31 (s, 3H, CH3); 13C NMR (151.0 
MHz, DMSO) δ: 169.50 (s, C(O)NH), 163.46 (s, C(O)), 163.24 (s, C(O)), 138.47, 134.11, 
133.29, 132.49, 129.29, 127.86, 124.28, 124.15, 122.80, 122.03, 120.93, 116.83, 42.21 (s, 
CH2CH=CH2), 24.56 (s, CH3C(O)). Anal. Calcd. for C17H14N2O3: C, 69.38; H, 4.79; N, 9.52; 
found: C, 69.14; H, 4.88; N, 9.76. 
 
General procedure for the preparation of acrylamides 11a-f 
To a solution of an appropriate 3-amino-1,8-naphthalimide 16a-f (1.00 mmol) in 
dichloromethane (2 mL) triethylamine (1.10 mmol) was added. The mixture was cooled in an 
ice bath and acryloyl chloride (1.05 mmol) was added dropwise. The reaction mixture was 
stirred for 24 h at room temperature and extracted with water (3 × 3 mL). Subsequently, the 
inorganic layer was extracted with ethyl ether (3 × 5 mL). The combined organic layers were 
dried over anhydrous MgSO4 and filtered. After evaporation of solvents the residue was 
purified on a silica column with chloroform:methanol mixtures (100:1, 50:1 v/v) to afford the 
respective acrylamides 11a-f. 
N OO
N
H
O
 
N-(2-propyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)propenamide 11a 
Yield: 57%; slightly yellowish amorphous solid (crystallized from chloroform/hexane) mp 
223–224°C; IR (KBr, cm-1) νmax: 3308, 2960, 1703, 1663, 1623, 1564, 1337, 1225, 786; 1H 
NMR (300 MHz, CDCl3) δ: 9.05 (s, 1H), 8.49 (dd, 1H, J = 7.3, 1.0 Hz), 8.30 (d, 1H, J = 2.2 
Hz), 8.17 (dd, 1H, J = 8.3, 1.0 Hz), 7.87 (br s, 1H, NH), 7.72 (dd, 1H, J = 8.3, 7.3 Hz), 6.55 
(dd, 1H, J = 16.8, 1.2 Hz, CH=CH2), 6.37 (dd, 1H, J = 16.8, 10.1 Hz, CH=CH2), 5.89 (dd, 1H, 
J = 10.1, 1.2 Hz, CH=CH2), 4.13 (t, 2H, J = 7.6 Hz, CH2CH2CH3), 1.79‒1.69 (m, 2H, 
CH2CH2CH3), 1.01 (t, 3H, J = 7.4 Hz, CH2CH2CH3); 13C NMR (151.0 MHz, DMSO) δ: 
164.24 (s, C(O)), 163.80 (s, C(O)), 163.58 (s, C(O)), 138.24, 134.12, 132.50, 131.97, 129.47, 
128.22, 128.00, 124.54, 124.30, 123.12, 122.27, 121.48, 41.73 (s, CH2CH2CH3), 21.31 (s, 
CH2CH2CH3), 18.82 (s, CH2CH2CH3); Anal. Calcd. for C18H16N2O3: C, 70.12; H, 5.23; N, 
9.09; found: C, 70.37; H, 5.13; N, 8.98. 
N OO
N
H
O
 
N-(2-butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)propenamide 11b 
Yield: 70%; slightly yellowish amorphous solid (crystallized from chloroform/hexane) mp 
235–236°C; IR (KBr, cm-1) νmax: 3258, 2956, 1696, 1661, 1624, 1547, 1338, 1269, 1227, 
1130, 786; 1H NMR (300 MHz, CDCl3) δ: 9.06 (d, 1H, J = 2.2 Hz), 8.49 (dd, 1H, J = 7.3, 1.0 
Hz), 8.30 (d, 1H, J = 2.2 Hz), 8.17 (dd, 1H, J = 8.3, 1.0 Hz), 7.80 (br s, 1H, NH), 7.73 (dd, 
1H, J = 8.3, 7.3 Hz), 6.55 (dd, 1H, J = 16.9, 1.2 Hz, CH=CH2), 6.36 (dd, 1H, J = 16.9, 10.1 
Hz, CH=CH2), 5.89 (dd, 1H, J = 10.1, 1.2 Hz, CH=CH2), 4.17 (t, 2H, J = 7.5 Hz, 
CH2CH2CH2CH3), 1.76‒1.66 (m, 2H, CH2CH2CH2CH3), 1.51‒1.41 (m, 2H, 
CH2CH2CH2CH3), 0.97 (t, 3H, J = 7.1 Hz, CH2CH2CH2CH3); 13C NMR (151.0 MHz, DMSO) 
δ: 164.24 (s, C(O)), 163.78 (s, C(O)), 163.55 (s, C(O)), 138.24, 134.13, 132.50, 131.97, 
129.47, 128.23, 128.01, 124.54, 124.31, 123.15, 122.30, 121.50, 40.43 (s, 
NCH2CH2CH2CH3), 30.11 (s, CH2CH2CH2CH3), 20.28 (s, CH2CH2CH2CH3), 14.15 (s, 
CH2CH2CH2CH3); Anal. Calcd. for C19H18N2O3: C, 70.79; H, 5.63; N, 8.69; found: C, 70.44; 
H, 5.78; N, 8.43. 
N OO
N
H
O
 
N-(2-isobutyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)propenamide 11c 
Yield: 76%; slightly yellowish amorphous solid (crystallized from chloroform/hexane) mp 
213–214°C; IR (KBr, cm-1) νmax: 3316, 2959, 1702, 1661, 1621, 1562, 1467, 1418, 1371, 
1337, 1264, 1227, 888, 787; 1H NMR (300 MHz, CDCl3) δ: 9.06 (d, 1H, J = 1.8 Hz), 8.49 
(dd, 1H, J = 7.2, 1.1 Hz), 8.31 (d, 1H, J = 1.8 Hz), 8.17 (dd, 1H, J = 8.1, 1.1 Hz), 7.89 (br s, 
1H, NH), 7.72 (dd, 1H, J = 8.1, 7.2 Hz), 6.55 (dd, 1H, J = 16.9, 1.2 Hz, CH=CH2), 6.38 (dd, 
1H, J = 16.9, 10.1 Hz, CH=CH2), 5.89 (dd, 1H, J = 10.1, 1.2 Hz, CH=CH2), 4.04 (d, 2H, J = 
7.3 Hz, CH2CH(CH3)2), 2.29‒2.16 (m, 1H, CH2CH(CH3)2), 0.97 (d, 6H, J = 6.5 Hz, 
CH2CH(CH3)2); 13C NMR (75.5 MHz, CDCl3) δ: 164.93 (s, C(O)), 164.66 (s, C(O)), 164.47 
(s, C(O)), 137.36, 134.02, 132.51, 130.84, 130.03, 128.37, 127.46, 124.94, 124.45, 122.79, 
122.71, 122.07, 47.43 (s, CH2CH(CH3)2), 27.57 (s, CH2CH(CH3)2), 20.42 (s, CH2CH(CH3)2); 
Anal. Calcd. for C19H18N2O3: C, 70.79; H, 5.63; N, 8.69; found: C, 70.63; H, 5.84; N, 8.44. 
N OO
N
H
N
O
 
N-(2-dimethylamino)ethyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-
yl)propenamide 11d 
Yield: 30%; yellowish amorphous solid (crystallized from chloroform/hexane) mp 208–
210°C; IR (KBr, cm-1) νmax: 3275, 3096, 2774, 1660, 1623, 1561, 1467, 1415, 1267, 1231, 
1138, 786; 1H NMR (300 MHz, CDCl3) δ: 8.67 (br s, 1H, NH), 8.64 (s, 1H), 8.33 (dd, 1H, J = 
7.3, 1.0 Hz), 7.99 (s, 1H), 7.90 (d, 1H, J = 8.2 Hz), 7.63 (dd, 1H, J = 8.2, 7.3 Hz), 6.52 (dd, 
1H, J = 16.9, 1.6 Hz, CH=CH2), 6.38 (dd, 1H, J = 16.9, 9.9 Hz, CH=CH2), 5.86 (dd, 1H, J = 
9.9, 1.6 Hz, CH=CH2), 4.35 (t, 2H, J = 6.1 Hz, CH2CH2N(CH3)2), 2.86 (t, 2H, J = 6.1 Hz, 
CH2CH2N(CH3)2), 2.49 (s, 6H, CH2CH2N(CH3)2); 13C NMR (75.5 MHz, CDCl3) δ: 164.37 (s, 
C(O)), 163.98 (s, C(O)), 163.35 (s, C(O)), 136.76, 133.62, 131.85, 130.95, 129.50, 128.43, 
127.28, 124.17, 123.55, 122.33, 121.67, 121.67, 57.85 (s, CH2CH2N(CH3)2), 46.05 (s, 
CH2CH2N(CH3)2), 37.89 (s, CH2CH2N(CH3)2); Anal. Calcd. for C19H19N3O3: C, 67.64; H, 
5.68; N, 12.46; found: C, 67.60; H, 5.43; N, 12.16. 
N OO
N
H
N
O
 
N-(2-diethylamino)ethyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-
yl)propenamide 11e 
Yield: 64%; yellowish amorphous solid (crystallized from chloroform/hexane) mp 196–
197°C; IR (KBr, cm-1) νmax: 3278, 2969, 1700, 1662, 1624, 1542, 1466, 1341, 1263, 1227, 
784; 1H NMR (300 MHz, CDCl3) δ: 8.96 (d, 1H, J = 2.1 Hz), 8.42 (dd, 1H, J = 7.2, 1.1 Hz), 
8.41 (br s, 1H, NH), 8.30 (d, 1H, J = 2.1 Hz), 8.08 (dd, 1H, J = 8.2, 1.1 Hz), 7.67 (dd, 1H, J = 
8.2, 7.2 Hz), 6.54 (dd, 1H, J = 16.9, 1.4 Hz, CH=CH2), 6.40 (dd, 1H, J = 16.9, 10.0 Hz, 
CH=CH2), 5.86 (dd, 1H, J = 10.0, 1.4 Hz, CH=CH2), 4.27‒4.22 (m, 2H, 
CH2CH2N(CH2CH3)2), 2.78‒2.73 (m, 2H, CH2CH2N(CH2CH3)2), 2.64 (q, 4H, J = 7.1 Hz, 
CH2CH2N(CH2CH3)2), 1.05 (t, 6H, J = 7.1 Hz, CH2CH2N(CH2CH3)2); 13C NMR (75.5 MHz, 
CDCl3) δ: 164.49 (s, C(O)), 163.84 (s, C(O)), 163.77 (s, C(O)), 136.85, 133.81, 132.29, 
130.83, 129.99, 128.90, 127.51, 124.84, 124.37, 122.88, 122.78, 122.00, 50.07 (s, 
CH2CH2N(CH2CH3)2), 47.66 (s, CH2CH2N(CH2CH3)2), 38.36 (s, CH2CH2N(CH2CH3)2), 
12.36 (s, CH2CH2N(CH2CH3)2); Anal. Calcd. for C21H23N3O3: C, 69.02; H, 6.34; N, 11.50; 
found: C, 68.88; H, 6.19; N, 11.34. 
N OO
N
H
N
O
 
N-(2-pirolidyn-1-yl)ethyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-
yl)propenamide 11f 
Yield: 43%; yellowish amorphous solid (crystallized from chloroform/hexane) mp 188–
189°C; IR (KBr, cm-1) νmax: 3254, 3096, 2966, 2786, 1698, 1661, 1562, 1467, 1418, 1349, 
1268, 1232, 1131, 787; 1H NMR (300 MHz, CDCl3) δ: 8.77 (d, 1H, J = 1.9 Hz), 8.37 (dd, 1H, 
J = 7.1, 1.0 Hz), 8.37 (br s, 1H, NH), 8.10 (d, 1H, J = 1.9 Hz), 7.99 (dd, 1H, J = 8.3, 1.0 Hz), 
7.66 (dd, 1H, J = 8.3, 7.1 Hz), 6.53 (dd, 1H, J = 16.9, 1.6 Hz, CH=CH2), 6.36 (dd, 1H, J = 
16.9, 10.1 Hz, CH=CH2), 5.87 (dd, 1H, J = 10.1, 1.6 Hz, CH=CH2), 4.37 (t, 2H, J = 6.6 Hz, 
CH2CH2N(CH2CH2)2), 2.94 (t, 2H, J = 6.6 Hz, CH2CH2N(CH2CH2)2), 2.80‒2.71 (m, 4H, 
CH2CH2N(CH2CH2)2), 1.86‒1.79 (m, 4H, CH2CH2N(CH2CH2)2); 13C NMR (75.5 MHz, 
CDCl3) δ: 164.25 (s, C(O)), 164.20 (s, C(O)), 163.60 (s, C(O)), 136.68, 133.83, 132.24, 
130.87, 129.87, 128.84, 127.60, 124.70, 123.70, 122.95, 122.11, 121.95, 54.87 (s, 
CH2CH2N(CH2CH2)2 and CH2CH2N(CH2CH2)2), 39.38 (s, CH2CH2N(CH2CH2)2), 23.91 (s, 
CH2CH2N(CH2CH2)2); Anal. Calcd. for C21H21N3O3: C, 69.41; H, 5.82; N, 11.56; found: C, 
69.53; H, 5.74; N, 11.67. 
 
General procedure for the preparation of isoxazolidines trans-9a–f and cis-9a–f 
A mixture of the nitrone 8 (1.00 mmol), acrylamide 11a–f (1.00 mmol) and toluene or a 
toluene-chloroform mixture (2 mL, 1:1, v/v) was stirred at 70°C for 24 h or until 
disappearance of the starting nitrone. After evaporation of solvents under reduced pressure the 
crude products were purified by silica gel chromatography with chloroform:methanol 
mixtures. 
O
N
(EtO)2(O)P
Me
O
HN
N O
O
 
Diethyl cis-5-(N-propylnaphthalimide-3-ylcarbamoyl)-2-methylisoxazolidin-3-yl-3-
phosphonate cis-9a 
Yellow oil; IR (film, cm-1) νmax: 3317, 2968, 2934, 1696, 1661, 1542, 1430, 1339, 1234, 1052, 
1025, 972; 1H NMR (300 MHz, CDCl3) δ: 9.31 (br s, 1H, NH), 8.94 (d, 1H, J = 2.1 Hz), 8.50 
(dd, 1H, J = 7.3, 1.0 Hz), 8.41 (d, 1H, J = 2.1 Hz), 8.18 (dd, 1H, J = 8.1, 1.0 Hz), 7.73 (dd, 
1H, J = 8.1, 7.3 Hz), 4.70 (dd, 1H, J = 8.7, 5.0 Hz, HC5), 4.24–4.05 (m, 6H, 2 × CH2OP and 
CH2CH2CH3), 3.20–2.98 (m, 2H, HC3 and HβC4), 3.02 (s, 3H, CH3N), 2.94–2.81 (m, 1H, 
HαC4), 1.80‒1.70 (m, 2H, CH2CH2CH3), 1.30 (t, 3H, J = 7.0 Hz, CH3CH2OP), 1.21 (t, 3H, J 
= 7.0 Hz, CH3CH2OP), 1.02 (t, 3H, J = 7.4 Hz, CH2CH2CH3); 13C NMR (151.0 MHz, CDCl3) 
δ: 170.81 (s, C(O)NH), 164.11 (s, C(O)), 163.81 (s, C(O)), 136.32, 133.63, 132.55, 129.90, 
127.49, 125.22, 124.20, 123.54, 122.55, 121.89, 76.02 (d, J = 6.8 Hz, C5), 63.72 (d, J = 169.4 
Hz, C3), 63.07 (d, J = 7.1 Hz, CH2OP), 62.02 (d, J = 6.8 Hz, CH2OP), 46.04 (d, J = 5.8 Hz, 
CH3N), 41.99 (s, CH2CH2CH3), 36.41 (s, C4), 21.39 (s, CH2CH2CH3), 16.43 (d, J = 6.0 Hz, 
CH3CH2OP), 16.36 (d, J = 5.6 Hz, CH3CH2OP), 11.49 (s, CH2CH2CH3); 31P NMR (121.5 
MHz, CDCl3) δ: 21.31. Anal. Calcd. for C24H30N3O7P: C, 57.25; H, 6.01; N, 8.35; found: C, 
57.32; H, 5.92; N, 8.48. 
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Diethyl trans-5-(N-propylnaphtalimide-3-ylcarbamoyl)-2-methylisoxazolidin-3-yl-3-
phosphonate trans-9a 
Yellowish amorphous solid (crystallized from chloroform/hexane) mp 175–176°C; IR (KBr, 
cm-1) νmax: 3241, 3067, 2967, 1697, 1664, 1567, 1339, 1266, 1214, 1049, 1018; 1H NMR (300 
MHz, CDCl3) δ: 8.93 (d, 1H, J = 2.2 Hz), 8.57 (br s, 1H, NH), 8.51 (dd, 1H, J = 7.2, 1.1 Hz), 
8.33 (d, 1H, J = 2.2 Hz), 8.18 (dd, 1H, J = 8.3, 1.1 Hz), 7.74 (dd, 1H, J = 8.3, 7.2 Hz), 4.69 
(dd, 1H, J = 8.7, 5.8 Hz, HC5), 4.29–4.14 (m, 4H, 2 × CH2OP), 4.15 (t, 2H, J = 7.5 Hz, 
CH2CH2CH3), 3.19–3.06 (m, 1H, HC3), 3.08 (s, 3H, CH3N), 3.07 (dddd, 1H, J = 16.1, 12.8, 
8.7, 8.7 Hz, HβC4), 2.88 (dddd, 1H, J = 12.8, 9.9, 8.2, 5.8 Hz, HαC4), 1.80‒1.72 (m, 2H, 
CH2CH2CH3), 1.39 (t, 3H, J = 7.0 Hz, CH3CH2OP), 1.37 (t, 3H, J = 7.0 Hz, CH3CH2OP), 
1.02 (t, 3H, J = 7.4 Hz, CH2CH2CH3); 13C NMR (75.5 MHz, CDCl3) δ: 169.45 (s, C(O)NH), 
163.72 (s, C(O)), 163.37 (s, C(O)), 135.71, 133.47, 132.18, 129.89, 127.46, 125.00, 124.00, 
123.25, 122.23, 122.12, 76.58 (d, J = 8.6 Hz, C5), 63.57 (d, J = 164.3 Hz, C3), 63.41 (d, J = 
6.3 Hz, CH2OP), 62.84 (d, J = 6.9 Hz, CH2OP), 46.84 (s, CH3N), 42.03 (s, CH2CH2CH3), 
36.52 (s, C4), 21.48 (s, CH2CH2CH3), 16.71 (d, J = 5.1 Hz, CH3CH2OP), 16.61 (d, J = 5.1 Hz, 
CH3CH2OP), 11.67 (s, CH2CH2CH3); 31P NMR (121.5 MHz, CDCl3) δ: 20.52. Anal. Calcd. 
for C24H30N3O7P: C, 57.25; H, 6.01; N, 8.35; found: C, 57.34; H, 5.92; N, 8.58. 
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Diethyl cis-5-(N-butylnaphthalimide-3-ylcarbamoyl)-2-methylisoxazolidin-3-yl-3-
phosphonate cis-9b 
Yellow oil; IR (film, cm-1) νmax: 2962, 2932, 1697, 1662, 1543, 1466, 1430, 1340, 1233, 1053, 
1026, 753; 1H NMR (300 MHz, CDCl3) δ: 9.30 (br s, 1H, NH), 8.94 (d, 1H, J = 2.1 Hz), 8.50 
(dd, 1H, J = 7.3, 1.2 Hz), 8.40 (d, 1H, J = 2.1 Hz), 8.17 (dd, 1H, J = 8.3, 1.2 Hz), 7.72 (dd, 
1H, J = 8.3, 7.3 Hz), 4.71–4.67 (m, 1H, HC5), 4.24–4.04 (m, 4H, 2 × CH2OP), 4.16 (t, 2H, J 
= 7.4 Hz, CH2CH2CH2CH3), 3.14–3.05 (m, 2H, HC3 and HβC4), 3.01 (d, 3H, J = 0.6 Hz, 
CH3N), 2.87–2.78 (m, 1H, HαC4), 1.77‒1.67 (m, 2H, CH2CH2CH2CH3), 1.51‒1.39 (m, 2H, 
CH2CH2CH2CH3), 1.30 (t, 3H, J = 7.1 Hz, CH3CH2OP), 1.21 (t, 3H, J = 7.0 Hz, CH3CH2OP), 
0.98 (t, 3H, J = 7.3 Hz, CH2CH2CH2CH3); 13C NMR (151.0 MHz, CDCl3) δ: 170.80 (s, 
C(O)NH), 164.09 (s, C(O)), 163.78 (s, C(O)), 136.31, 133.62, 132.53, 129.87, 127.48, 
125.19, 124.18, 123.52, 122.54, 121.87, 76.01 (d, J = 6.8 Hz, C5), 63.70 (d, J = 169.6 Hz, 
C3), 63.07 (d, J = 6.3 Hz, CH2OP), 62.03 (d, J = 6.4 Hz, CH2OP), 46.03 (d, J = 5.8 Hz, 
CH3N), 40.28 (s, CH2CH2N(CH3)2), 36.39 (s, C4), 30.21 (s, CH2CH2CH2CH3), 20.35 (s, 
CH2CH2CH2CH3), 16.43 (d, J = 5.8 Hz, CH3CH2OP), 16.35 (d, J = 5.9 Hz, CH3CH2OP), 
13.81 (s, CH2CH2CH2CH3); 31P NMR (121.5 MHz, CDCl3) δ: 21.37. Anal. Calcd. for 
C25H32N3O7P: C, 58.02; H, 6.23; N, 8.12; found: C, 58.30; H, 6.23; N, 8.00. 
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Diethyl trans-5-(N-butylnaphthalimide-3-ylcarbamoyl)-2-methylisoxazolidin-3-yl-3-
phosphonate trans-9b 
Yellowish amorphous solid (crystallized from chloroform/hexane) mp 157–158°C; IR (KBr, 
cm-1) νmax: 3278, 2958, 1698, 1661, 1565, 1341, 1229, 1052, 1033, 970; 1H NMR (300 MHz, 
CDCl3) δ: 8.93 (d, 1H, J = 2.2 Hz), 8.57 (br s, 1H, NH), 8.51 (dd, 1H, J = 7.3, 1.2 Hz), 8.33 
(d, 1H, J = 2.2 Hz), 8.18 (dd, 1H, J = 8.3, 1.2 Hz), 7.74 (dd, 1H, J = 8.3, 7.3 Hz), 4.69 (dd, 
1H, J = 8.5, 5.6 Hz, HC5), 4.29–4.16 (m, 4H, 2 × CH2OP), 4.18 (t, 2H, J = 7.4 Hz, 
CH2CH2CH2CH3), 3.18–3.05 (m, 1H, HC3), 3.07 (s, 3H, CH3N), 3.07 (dddd, 1H, J = 15.9, 
12.7, 8.5, 8.5 Hz, HβC4), 2.88 (dddd, 1H, J = 12.7, 10.1, 8.1, 5.6 Hz, HαC4), 1.76‒1.66 (m, 
2H, CH2CH2CH2CH3), 1.51‒1.39 (m, 2H, CH2CH2CH2CH3), 1.38 (t, 3H, J = 7.1 Hz, 
CH3CH2OP), 1.37 (t, 3H, J = 7.1 Hz, CH3CH2OP), 0.98 (t, 3H, J = 7.3 Hz, CH2CH2CH2CH3); 
13C NMR (75.5 MHz, CDCl3) δ: 169.47 (s, C(O)NH), 163.79 (s, C(O)), 163.45 (s, C(O)), 
135.70, 133.55, 132.26, 129.98, 127.54, 125.10, 124.01, 123.36, 122.33, 122.17, 76.59 (d, J = 
8.9 Hz, C5), 63.59 (d, J = 167.2 Hz, C3), 63.47 (d, J = 6.6 Hz, CH2OP), 62.87 (d, J = 6.9 Hz, 
CH2OP), 46.86 (s, CH3N), 40.37 (s, CH2CH2CH2CH3), 36.56 (s, C4), 30.31 (s, 
CH2CH2CH2CH3), 20.51 (s, CH2CH2CH2CH3), 16.74 (d, J = 5.1 Hz, CH3CH2OP), 16.64 (d, J 
= 5.1 Hz, CH3CH2OP), 14.02 (s, CH2CH2CH2CH3); 31P NMR (121.5 MHz, CDCl3) δ: 20.55. 
Anal. Calcd. for C25H32N3O7P: C, 58.02; H, 6.23; N, 8.12; found: C, 58.13; H, 6.20; N, 7.92. 
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Diethyl cis-5-(N-isobutylnaphthalimide-3-ylcarbamoyl)-2-methylisoxazolidin-3-yl-3-
phosphonate cis-9c 
Yellow oil; IR (film, cm-1) νmax: 2963, 1701, 1662, 1543, 1337, 1234, 1054, 1027, 755; 1H 
NMR (300 MHz, CDCl3) δ: 9.30 (br s, 1H, NH), 8.95 (d, 1H, J = 2.2 Hz), 8.50 (dd, 1H, J = 
7.3, 1.1 Hz), 8.40 (d, 1H, J = 2.2 Hz), 8.18 (dd, 1H, J = 8.3, 1.1 Hz), 7.73 (dd, 1H, J = 8.3, 7.3 
Hz), 4.69 (dd, 1H, J = 8.3, 4.6 Hz, HC5), 4.24–4.02 (m, 4H, 2 × CH2OP), 4.05 (d, 2H, J = 7.3 
Hz, CH2CH(CH3)2), 3.16–3.01 (m, 2H, HC3 and HβC4), 3.01 (d, 3H, J = 1.0 Hz, CH3N), 
2.93–2.83 (m, 1H, HαC4), 2.28‒2.19 (m, 1H, CH2CH(CH3)2), 1.30 (t, 3H, J = 7.0 Hz, 
CH3CH2OP), 1.21 (t, 3H, J = 7.1 Hz, CH3CH2OP), 0.99 (d, 6H, J = 6.7 Hz, CH2CH(CH3)2); 
13C NMR (151.0 MHz, CDCl3) δ: 170.80 (s, C(O)NH), 164.37 (s, C(O)), 164.08 (s, C(O)), 
136.33, 133.59, 132.52, 129.95, 127.48, 125.23, 124.29, 123.46, 122.48, 121.86, 76.01 (d, J = 
6.8 Hz, C5), 63.70 (d, J = 166.5 Hz, C3), 63.06 (d, J = 6.5 Hz, CH2OP), 63.02 (d, J = 6.8 Hz, 
CH2OP), 47.21 (s, CH2CH(CH3)2), 46.01 (d, J = 5.7 Hz, CH3N), 36.39 (s, C4), 27.39 (s, 
CH2CH(CH3)2), 20.28 (s, CH2CH(CH3)2), 16.42 (d, J = 5.6 Hz, CH3CH2OP), 16.34 (d, J = 5.6 
Hz, CH3CH2OP); 31P NMR (121.5 MHz, CDCl3) δ: 21.36. Anal. Calcd. for C25H32N3O7P: C, 
58.02; H, 6.23; N, 8.12; found: C, 58.15; H, 6.25; N, 7.87. 
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Diethyl trans-5-(N-isobutylnaphthalimide-3-ylcarbamoyl)-2-methylisoxazolidin-3-yl-3-
phosphonate trans-9c 
Yellowish amorphous solid (crystallized from chloroform/hexane) mp 165–166°C; IR (KBr, 
cm-1) νmax: 3273, 3243, 2986, 2955, 1699, 1661, 1564, 1337, 1228, 1052, 1034, 973, 783; 1H 
NMR (300 MHz, CDCl3) δ: 8.93 (d, 1H, J = 2.2 Hz), 8.57 (br s, 1H, NH), 8.51 (dd, 1H, J = 
7.3, 1.0 Hz), 8.33 (d, 1H, J = 2.2 Hz), 8.17 (dd, 1H, J = 8.3, 1.2 Hz), 7.74 (dd, 1H, J = 8.3, 7.3 
Hz), 4.69 (dd, 1H, J = 8.7, 5.7 Hz, HC5), 4.29–4.18 (m, 4H, 2 × CH2OP), 4.04 (d, 2H, J = 7.5 
Hz, CH2CH(CH3)2), 3.16–3.05 (m, 1H), 3.07 (s, 3H, CH3N), 3.06 (dddd, 1H, J = 15.7, 12.8, 
8.7, 8.7 Hz, HβC4), 2.87 (dddd, 1H, J = 12.8, 10.3, 8.1, 5.7 Hz, HαC4), 2.28‒2.19 (m, 1H, 
CH2CH(CH3)2), 1.38 (t, 3H, J = 7.1 Hz, CH3CH2OP), 1.37 (t, 3H, J = 7.1 Hz, CH3CH2OP), 
0.98 (d, 6H, J = 6.5 Hz, CH2CH(CH3)2); 13C NMR (75.5 MHz, CDCl3) δ: 169.47 (s, 
C(O)NH), 164.21 (s, C(O)), 163.90 (s, C(O)), 135.69, 133.65, 132.43, 130.23, 127.68, 
125.34, 124.13, 123.53, 122.46, 122.26, 76.53 (d, J = 8.9 Hz, C5), 63.68 (d, J = 166.9 Hz, 
C3), 63.54 (d, J = 6.6 Hz, CH2OP), 62.89 (d, J = 6.9 Hz, CH2OP), 47.38 (s, CH2CH(CH3)2), 
46.93 (br s, CH3N), 36.72 (s, C4), 27.60 (s, CH2CH(CH3)2), 20.52 (s, CH2CH(CH3)2), 16.78 
(d, J = 5.1 Hz, CH3CH2OP), 16.71 (d, J = 5.4 Hz, CH3CH2OP); 31P NMR (121.5 MHz, 
CDCl3) δ: 20.53. Anal. Calcd. for C25H32N3O7P: C, 58.02; H, 6.23; N, 8.12; found: C, 58.12; 
H, 5.99; N, 7.88. 
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Diethyl cis-5-[N-(2-dimethylamino)ethylnaphthalimide-3-ylcarbamoyl]-2-
methylisoxazolidin-3-yl-3-phosphonate cis-9d 
Yellow amorphous solid; mp 119–120°C; IR (KBr, cm-1) νmax: 3274, 2980, 2776, 1695, 1662, 
1544, 1465, 1430, 1341, 1237, 1026, 971, 751; 1H NMR (300 MHz, CDCl3) δ: 9.29 (br s, 1H, 
NH), 8.95 (d, 1H, J = 2.2 Hz), 8.50 (dd, 1H, J = 7.4, 1.2 Hz), 8.41 (d, 1H, J = 2.2 Hz), 8.18 (d, 
1H, J = 8.3 Hz), 7.72 (dd, 1H, J = 8.3, 7.4 Hz), 4.69 (dd, 1H, J = 8.9, 4.8 Hz, HC5), 4.34 (t, 
2H, J = 6.9 Hz, CH2CH2N(CH3)2), 4.23–4.05 (m, 4H, 2 × CH2OP), 3.18–3.00 (m, 2H, HC3 
and HβC4), 3.01 (s, 3H, CH3N), 2.87–2.78 (m, 1H, HαC4), 2.69 (t, 2H, J = 6.9 Hz, 
CH2CH2N(CH3)2), 2.38 (s, 6H, CH2CH2N(CH3)2), 1.30 (t, 3H, J = 7.0 Hz, CH3CH2OP), 1.20 
(t, 3H, J = 7.0 Hz, CH3CH2OP); 13C NMR (151.0 MHz, CDCl3) δ: 170.83 (s, C(O)NH), 
164.13 (s, C(O)), 163.83 (s, C(O)), 136.33, 133.73, 132.56, 129.98, 127.49, 125.26, 124.25, 
123.45, 122.46, 121.93, 76.00 (d, J = 6.8 Hz, C5), 63.71 (d, J = 169.5 Hz, C3), 63.07 (d, J = 
6.7 Hz, CH2OP), 63.02 (d, J = 7.0 Hz, CH2OP), 56.95 (s, CH2CH2N(CH3)2), 46.03 (d, J = 5.9 
Hz, CH3N), 45.67 (s, CH2CH2N(CH3)2), 38.15 (s, CH2CH2N(CH3)2), 36.41 (s, C4), 16.43 (d, 
J = 5.6 Hz, CH3CH2OP), 16.36 (d, J = 5.9 Hz, CH3CH2OP); 31P NMR (121.5 MHz, CDCl3) δ: 
21.32. Anal. Calcd. for C25H33N4O7P: C, 56.39; H, 6.25; N, 10.52; found: C, 56.20; H, 6.49; 
N, 10.39. 
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Diethyl trans-5-[N-(2-dimethylamino)ethylnaphthalimide-3-ylcarbamoyl]-2-
methylisoxazolidin-3-yl-3-phosphonate trans-9d 
Yellowish oil; IR (film, cm-1) νmax: 3248, 3092, 2943, 2776, 1700, 1662, 1562, 1465, 1430, 
1340, 1236, 1052, 1025, 970, 751; 1H NMR (300 MHz, CDCl3) δ: 8.91 (d, 1H, J = 2.1 Hz), 
8.61 (br s, 1H, NH), 8.50 (d, 1H, J = 7.1 Hz), 8.32 (d, 1H, J = 2.1 Hz), 8.16 (d, 1H, J = 8.5 
Hz), 7.73 (dd, 1H, J = 8.5, 7.1 Hz), 4.69 (dd, 1H, J = 8.7, 5.8 Hz, HC5), 4.33 (t, 2H, J = 6.8 
Hz, CH2CH2N(CH3)2), 4.29–4.16 (m, 4H, 2 × CH2OP), 3.18–3.05 (m, 1H, HC3), 3.07 (s, 3H, 
CH3N), 3.06 (dddd, 1H, J = 16.0, 12.8, 8.7, 8.7 Hz, HβC4), 2.88 (dddd, 1H, J = 12.8, 9.6, 8.2, 
5.8 Hz, HαC4), 2.66 (t, 2H, J = 6.8 Hz, CH2CH2N(CH3)2), 2.36 (s, 6H, CH2CH2N(CH3)2), 
1.38 (t, 3H, J = 7.1 Hz, CH3CH2OP), 1.37 (t, 3H, J = 7.0 Hz, CH3CH2OP); 13C NMR (75.5 
MHz, CDCl3) δ: 169.42 (s, C(O)NH), 163.92 (s, C(O)), 163.53 (s, C(O)), 135.71, 133.69, 
132.30, 130.08, 127.58, 125.13, 123.93, 123.31, 122.28, 122.09, 76.57 (d, J = 8.9 Hz, C5), 
63.65 (d, J = 170.9 Hz, C3), 63.50 (d, J = 6.6 Hz, CH2OP), 62.86 (d, J = 6.9 Hz, CH2OP), 
57.21 (s, CH2CH2N(CH3)2), 46.95 (s, CH3N), 45.90 (s, CH2CH2N(CH3)2), 38.33 (s, 
CH2CH2N(CH3)2), 36.57 (s, C4), 16.79 (d, J = 5.1 Hz, CH3CH2OP), 16.68 (d, J = 5.2 Hz, 
CH3CH2OP); 31P NMR (121.5 MHz, CDCl3) δ: 20.56. Anal. Calcd. for C25H33N4O7P: C, 
56.39; H, 6.25; N, 10.52; found: C, 56.18; H, 6.48; N, 10.45. 
O
N
(EtO)2(O)P
Me
O
HN
N O
O
N
 
Diethyl cis-5-[N-(2-diethylamino)ethylnaphthalimide-3-ylcarbamoyl]-2-
methylisoxazolidin-3-yl-3-phosphonate cis-9e 
Yellowish oil; IR (film, cm-1) νmax: 3301, 2973, 2932, 1696, 1662, 1544, 1466, 1430, 1342, 
1235, 1026, 972, 785; 1H NMR (300 MHz, CDCl3) δ: 9.29 (br s, 1H, NH), 8.95 (d, 1H, J = 
2.2 Hz), 8.49 (dd, 1H, J = 7.3, 1.2 Hz), 8.40 (d, 1H, J = 2.2 Hz), 8.18 (d, 1H, J = 8.3 Hz), 7.72 
(dd, 1H, J = 8.3, 7.3 Hz), 4.69 (dd, 1H, J = 8.7, 4.7 Hz, HC5), 4.31 (t, 2H, J = 7.1 Hz, 
CH2CH2N(CH2CH3)2), 4.23–4.04 (m, 4H, 2 × CH2OP), 3.20–2.98 (m, 2H, HC3 and HβC4), 
3.01 (s, 3H, CH3N), 2.98–2.80 (m, 1H, HαC4), 2.83 (t, 2H, J = 7.1 Hz, CH2CH2N(CH2CH3)2), 
2.69 (q, 4H, J = 7.0 Hz, CH2CH2N(CH2CH3)2), 1.29 (t, 3H, J = 7.0 Hz, CH3CH2OP), 1.20 (t, 
3H, J = 7.0 Hz, CH3CH2OP), 1.11 (t, 6H, J = 7.0 Hz, CH2CH2N(CH2CH3)2); 13C NMR (151.0 
MHz, CDCl3) δ: 170.86 (s, C(O)NH), 164.08 (s, C(O)), 163.78 (s, C(O)), 136.34, 133.77, 
132.60, 129.95, 127.53, 125.23, 124.20, 123.44, 122.45, 121.98, 76.01 (d, J = 6.8 Hz, C5), 
63.71 (d, J = 169.4 Hz, C3), 63.08 (d, J = 6.7 Hz, CH2OP), 63.01 (d, J = 6.8 Hz, CH2OP), 
49.69 (s, CH2CH2N(CH2CH3)2), 47.67 (s, CH2CH2N(CH2CH3)2), 46.04 (d, J = 5.8 Hz, 
CH3N), 37.85 (s, CH2CH2N(CH2CH3)2), 36.45 (s, C4), 16.43 (d, J = 5.6 Hz, CH3CH2OP), 
16.36 (d, J = 6.0 Hz, CH3CH2OP), 12.06 (s, CH2CH2N(CH2CH3)2); 31P NMR (121.5 MHz, 
CDCl3) δ: 21.31. Anal. Calcd. for C27H37N4O7P: C, 57.85; H, 6.65; N, 9.99; found: C, 57.67; 
H, 6.62; N, 9.85. 
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Diethyl trans-5-[N-(2-diethylamino)ethylnaphthalimide-3-ylcarbamoyl]-2-
methylisoxazolidin-3-yl-3-phosphonate trans-9a 
Yellowish oil; IR (film, cm-1) νmax: 3249, 2974, 2933, 1698, 1662, 1563, 1466, 1430, 1341, 
1235, 1054, 1027, 972, 755; 1H NMR (600 MHz, CDCl3) δ: 8.93 (d, 1H, J = 2.2 Hz), 8.64 (br 
s, 1H, NH), 8.51 (dd, 1H, J = 7.3, 0.8 Hz), 8.35 (d, 1H, J = 2.2 Hz), 8.18 (d, 1H, J = 8.0 Hz), 
7.74 (dd, 1H, J = 8.0, 7.3 Hz), 4.71 (dd, 1H, J = 8.8, 5.6 Hz, HC5), 4.30 (t, 2H, J = 7.5 Hz, 
CH2CH2N(CH2CH3)2), 4.28–4.19 (m, 4H, 2 × CH2OP), 3.18–3.11 (m, 1H, HC3), 3.09 (s, 3H, 
CH3N), 3.08 (dddd, 1H, J = 16.0, 12.7, 8.8, 8.8 Hz, HβC4), 2.89 (dddd, 1H, J = 12.7, 9.5, 8.3, 
5.6 Hz, HαC4), 2.80 (t, 2H, J = 7.5 Hz, CH2CH2N(CH2CH3)2), 2.68 (q, 4H, J = 7.1 Hz, 
CH2CH2N(CH2CH3)2), 1.40 (t, 3H, J = 7.0 Hz, CH3CH2OP), 1.38 (t, 3H, J = 7.0 Hz, 
CH3CH2OP), 1.10 (t, 6H, J = 7.1 Hz, CH2CH2N(CH2CH3)2); 13C NMR (75.5 MHz, CDCl3) δ: 
169.46 (s, C(O)NH), 163.81 (s, C(O)), 163.47 (s, C(O)), 135.71, 133.68, 132.34, 130.04, 
127.59, 125.16, 124.01, 123.35, 122.32, 122.23, 76.57 (d, J = 7.7 Hz, C5), 63.64 (d, J = 167.8 
Hz, C3), 63.48 (d, J = 6.6 Hz, CH2OP), 62.86 (d, J = 6.9 Hz, CH2OP), 49.87 (s, 
CH2CH2N(CH2CH3)2), 47.72 (s, CH2CH2N(CH2CH3)2), 46.96 (s, CH3N), 38.16 (s, 
CH2CH2N(CH2CH3)2), 36.63 (s, C4), 16.76 (d, J = 4.9 Hz, CH3CH2OP), 16.65 (d, J = 5.4 Hz, 
CH3CH2OP), 12.36 (s, CH2CH2N(CH2CH3)2); 31P NMR (243.0 MHz, CDCl3) δ: 20.17. Anal. 
Calcd. for C27H37N4O7P: C, 57.85; H, 6.65; N, 9.99; found: C, 57.87; H, 6.71; N, 9.91. 
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Diethyl cis-5-[N-(2-pirolidyn-1-yl)ethylnaphthalimide-3-ylcarbamoyl]-2-
methylisoxazolidin-3-yl-3-phosphonate cis-9f 
Yellowish oil; IR (film, cm-1) νmax: 3276, 2971, 2791, 1691, 1662, 1543, 1430, 1338, 1234, 
1052, 971, 785, 750; 1H NMR (600 MHz, CDCl3) δ: 9.30 (br s, 1H, NH), 8.96 (d, 1H, J = 2.0 
Hz), 8.52 (d, 1H, J = 7.2 Hz), 8.43 (d, 1H, J = 2.0 Hz), 8.19 (d, 1H, J = 8.1 Hz), 7.74 (dd, 1H, 
J = 8.1, 7.2 Hz), 4.71 (dd, 1H, J = 9.2, 5.0 Hz, HC5), 4.40 (t, 2H, J = 7.3 Hz, 
CH2CH2N(CH2CH2)2), 4.24–4.08 (m, 4H, 2 × CH2OP), 3.15–3.08 (m, 2H, HC3 and HβC4), 
3.04 (s, 3H, CH3N), 2.93–2.88 (m, 1H, HαC4), 2.88–2.83 (m, 2H, CH2CH2N(CH2CH2)2), 2.71 
(br s, 4H, CH2CH2N(CH2CH2)2), 1.83 (br s, 4H, CH2CH2N(CH2CH2)2, 1.32 (t, 3H, J = 7.0 
Hz, CH3CH2OP), 1.23 (t, 3H, J = 7.0 Hz, CH3CH2OP); 13C NMR (151.0 MHz, CDCl3) δ: 
170.84 (s, C(O)NH), 164.07 (s, C(O)), 163.75 (s, C(O)), 136.32, 133.72, 132.58, 129.95, 
127.50, 125.26, 124.21, 123.50, 122.51, 121.92, 76.00 (d, J = 7.3 Hz, C5), 63.72 (d, J = 169.1 
Hz, C3), 63.08 (d, J = 6.7 Hz, CH2OP), 62.99 (d, J = 6.8 Hz, CH2OP), 54.35 (s, 
CH2CH2N(CH2CH2)2), 53.63 (s, CH2CH2N(CH2CH2)2), 46.04 (d, J = 5.7 Hz, CH3N), 39.21 
(s, CH2CH2N(CH2CH3)2), 36.44 (s, C4), 23.64 (s, CH2CH2N(CH2CH2)2, 16.43 (d, J = 5.7 Hz, 
CH3CH2OP), 16.36 (d, J = 5.6 Hz, CH3CH2OP); 31P NMR (243 MHz, CDCl3) δ: 20.86. Anal. 
Calcd. for C27H35N4O7P: C, 58.06; H, 6.32; N, 10.03; found: C, 57.84; H, 6.39; N, 9.75. 
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Diethyl trans-5-[N-(2-pirolidyn-1-yl)ethylnaphthalimide-3-ylcarbamoyl]-2-
methylisoxazolidin-3-yl-3-phosphonate trans-9f 
Yellowish oil; IR (film, cm-1) νmax: 3271, 2970, 1698, 1661, 1563, 1465, 1430, 1337, 1233, 
1027, 970, 784, 749; 1H NMR (600 MHz, CDCl3) δ: 8.94 (d, 1H, J = 2.1 Hz), 8.60 (br s, 1H, 
NH), 8.53 (dd, 1H, J = 7.3, 0.9 Hz), 8.36 (d, 1H, J = 2.1 Hz), 8.19 (d, 1H, J = 8.0 Hz), 7.76 
(dd, 1H, J = 8.0, 7.3 Hz), 4.71 (dd, 1H, J = 8.9, 5.5 Hz, HC5), 4.39 (t, 2H, J = 7.3 Hz, 
CH2CH2N(CH2CH2)2), 4.29–4.19 (m, 4H, 2 × CH2OP), 3.17–3.09 (m, 1H, HC3), 3.10 (s, 3H, 
CH3N), 3.08 (dddd, 1H, J = 16.1, 12.9, 8.9, 8.9 Hz, HβC4), 2.89 (dddd, 1H, J = 12.9, 9.4, 8.3, 
5.5 Hz, HαC4), 2.85 (t, 2H, J = 7.3 Hz, CH2CH2N(CH2CH2)2), 2.70 (br s, 4H, 
CH2CH2N(CH2CH2)2), 1.82 (br s, 4H, CH2CH2N(CH2CH2)2), 1.41 (t, 3H, J = 7.1 Hz, 
CH3CH2OP), 1.39 (t, 3H, J = 7.1 Hz, CH3CH2OP); 13C NMR (151.0 MHz, CDCl3) δ: 169.48 
(s, C(O)NH), 163.88 (s, C(O)), 163.55 (s, C(O)), 135.68, 133.64, 132.40, 130.09, 127.59, 
125.27, 123.97, 123.49, 122.43, 122.20, 76.38 (d, J = 8.9 Hz, C5), 63.67 (d, J = 170.4 Hz, 
C3), 63.35 (d, J = 6.5 Hz, CH2OP), 62.69 (d, J = 6.9 Hz, CH2OP), 54.34 (s, 
CH2CH2N(CH2CH2)2), 53.64 (s, CH2CH2N(CH2CH2)2), 46.72 (s, CH3N), 39.27 (s, 
CH2CH2N(CH2CH3)2), 36.56 (s, C4), 23.61 (s, CH2CH2N(CH2CH2)2, 16.52 (d, J = 5.9 Hz, 
CH3CH2OP), 16.45 (d, J = 5.7 Hz, CH3CH2OP); 31P NMR (243.0 MHz, CDCl3) δ: 20.13. 
Anal. Calcd. for C27H35N4O7P: C, 58.06; H, 6.32; N, 10.03; found: C, 58.22; H, 6.28; N, 9.83. 
 
General procedure for the preparation of isoxazolidines trans-10a–d and cis-9a–d 
A mixture of the nitrone 8 (1.00 mmol), N-(2-propenyl)naphthalimide 12a–d (1.00 mmol) and 
toluene or a toluene–chloroform mixture (2 mL, 1:1, v/v) was stirred at 70°C for 24 h or until 
disappearance of the starting nitrone. After evaporation of solvents under reduced pressure the 
crude products were purified by silica gel chromatography with chloroform:methanol 
mixtures. 
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Diethyl 5-(1,3-dioxo-2,3-dihydro-1H-benzo[de]izochinolin-2-ylmethyl)-2-
methylisoxazolidin-3-yl-3-phosphonate trans-10a 
White amorphous solid (crystallized from chloroform/hexane) mp 175–176°C; IR (KBr, cm-1) 
νmax: 2981, 1702, 1662, 1591, 1328, 1234, 1056, 1035, 973; (signals of trans-10a were 
extracted from the spectra of a 93:7 mixture of trans-10a and cis-10a); 1H NMR (300 MHz, 
CDCl3) δ: 8.61 (dd, 2H, J = 7.2, 1.1 Hz), 8.23 (dd, 2H, J = 8.1, 1.1 Hz), 7.76 (dd, 2H, J = 8.1, 
7.2 Hz), 4.56–4.44 (m, 2H, HC5 and CH2N), 4.33–4.28 (m, 1H, CH2N), 4.22–4.11 (m, 4H, 2 
× CH2OP), 3.09 (ddd, 1H, J = 9.5, 7.2, 2.3 Hz, HC3), 2.89 (d, 3H, J = 0.8 Hz, CH3N), 2.65 
(dddd, 1H, J = 18.0, 12.5, 7.2, 7.2 Hz, HβC4), 2.44 (dddd, 1H, J = 12.5, 11.6, 9.5, 6.9 Hz, 
HαC4), 1.33 (t, 3H, J = 7.0 Hz, CH3CH2OP), 1.32 (t, 3H, J = 7.0 Hz, CH3CH2OP); 13C NMR 
(75.5 MHz, CDCl3) δ: 164.16 (s, 2 × C(O)), 134.14, 131.60, 131.47, 128.21, 126.98, 122.50, 
74.96 (d, J = 7.6 Hz, C5), 64.06 (d, J = 168.6 Hz, C3), 63.34 (d, J = 6.6 Hz, CH2OP), 62.53 
(d, J = 6.9 Hz, CH2OP), 46.71 (br s, CH3N), 42.77 (s, CH2N), 36.55 (s, C4), 16.81 (d, J = 6.0 
Hz, CH3CH2OP), 16.73 (d, J = 6.0 Hz, CH3CH2OP); 31P NMR (121.5 MHz, CDCl3) δ: 22.67. 
Anal. Calcd. for C21H25N2O6P: C, 58.33; H, 5.83; N, 6.48; found: C, 58.28; H, 5.59; N, 6.61 
(obtained on a 93:7 mixture of trans-10a and cis-10a). 
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Diethyl 5-(5-nitro-1,3-dioxo-2,3-dihydro-1H-benzo[de]izochinolin-2-ylmethyl)-2-
methylisoxazolidin-3-yl-3-phosphonate trans-10b 
Grey amorphous solid (crystallized from chloroform/hexane) mp 197–198°C; IR (KBr, cm-1) 
νmax: 2985, 1715, 1672, 1600, 1541, 1343, 1326, 1233, 1033, 974, 799; (signals of trans-10b 
were extracted from the spectra of a 94:6 mixture of trans-10b and cis-10b); 1H NMR (300 
MHz, CDCl3) δ: 9.32 (d, 1H, J = 2.2 Hz), 9.14 (d, 1H, J = 2.2 Hz), 8.79 (dd, 1H, J = 7.3, 1.2 
Hz), 8.44 (dd, 1H, J = 8.2, 1.2 Hz), 7.95 (dd, 1H, J = 8.2, 7.3 Hz), 4.56 (dd, 1H, J = 12.5, 7.7 
Hz, CH2N), 4.47 (dddd, 1H, J = 7.7, 7.2, 7.2, 4.0 Hz, HC5), 4.30 (dd, 1H, J = 12.5, 4.0 Hz, 
CH2N), 4.25–4.12 (m, 4H, 2 × CH2OP), 3.09 (ddd, 1H, J = 9.6, 7.2, 2.4 Hz, HC3), 2.88 (d, 
3H, J = 1.0 Hz, CH3N), 2.69 (dddd, 1H, J = 18.1, 12.5, 7.2, 7.2 Hz, HαC4), 2.41 (dddd, 1H, J 
= 12.5, 11.9, 9.6, 7.2 Hz, HβC4), 1.34 (t, 3H, J = 7.1 Hz, CH3CH2OP), 1.33 (t, 3H, J = 7.0 Hz, 
CH3CH2OP); 13C NMR (75.5 MHz, CDCl3) δ: 163.07 (s, C(O)), 162.50 (s, C(O)), 146.43, 
135.66, 134.61, 131.04, 130.24, 129.09, 129.02, 124.55, 124.44, 123.07, 74.53 (d, J = 7.6 Hz, 
C5), 63.94 (d, J = 169.3 Hz, C3), 63.13 (d, J = 6.5 Hz, CH2OP), 62.42 (d, J = 6.7 Hz, 
CH2OP), 46.46 (s, CH3N), 43.05 (s, CH2N), 36.34 (s, C4), 16.51 (d, J = 6.3 Hz, CH3CH2OP), 
16.47 (d, J = 6.1 Hz, CH3CH2OP); 31P NMR (121.5 MHz, CDCl3) δ: 22.49. Anal. Calcd. for 
C21H24N3O8P: C, 52.83; H, 5.07; N, 8.80; found: C, 52.73; H, 4.82; N, 8.52 (obtained on a 
94:6 mixture of trans-10b and cis-10b). 
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Diethyl 5-(5-amino-1,3-dioxo-2,3-dihydro-1H-benzo[de]izochinolin-2-ylmethyl)-2-
methylisoxazolidin-3-yl-3-phosphonate trans-10c 
Yellow amorphous solid (crystallized from chloroform/hexane) mp 126–127°C; IR (KBr, cm-
1) νmax: 3431, 3353, 1692, 1651, 1619, 1236, 1056, 1021, 969, 778; (signals of trans-10c were 
extracted from the spectra of a 93:7 mixture of trans-10c and cis-10c); 1H NMR (300 MHz, 
CDCl3) δ: 8.30 (dd, 1H, J = 7.3, 1.0 Hz), 8.00 (d, 1H, J = 2.3 Hz), 7.93 (dd, 1H, J = 8.2, 1.0 
Hz), 7.59 (dd, 1H, J = 8.2, 7.3 Hz), 7.29 (d, 1H, J = 2.3 Hz), 4.53–4.42 (m, 2H, HC5 and 
CH2N), 4.31–4.25 (m, 1H, CH2N), 4.23–4.11 (m, 4H, 2 × CH2OP), 3.09 (ddd, 1H, J = 9.6, 
7.2, 2.2 Hz, HC3), 2.89 (d, 3H, J = 0.8 Hz, CH3N), 2.64 (dddd, 1H, J = 18.2, 12.5, 7.2, 7.2 
Hz, HαC4), 2.43 (dddd, 1H, J = 12.5, 11.8, 9.6, 7.2 Hz, HβC4), 1.33 (t, 3H, J = 7.1 Hz, 
CH3CH2OP), 1.32 (t, 3H, J = 7.1 Hz, CH3CH2OP); 13C NMR (75.5 MHz, CDCl3) δ: 164.41 
(s, C(O)), 164.12 (s, C(O)), 145.70, 133.25, 131.78, 127.23, 126.91, 123.04, 122.85, 122.07, 
121.87, 113.86, 75.17 (d, J = 7.4 Hz, C5), 63.92 (d, J = 170.9 Hz, C3), 63.26 (d, J = 6.5 Hz, 
CH2OP), 62.74 (d, J = 6.9 Hz, CH2OP), 46.76 (br s, CH3N), 42.64 (s, CH2N), 36.36 (s, C4), 
16.77 (d, J = 5.7 Hz, CH3CH2OP), 16.70 (d, J = 5.7 Hz, CH3CH2OP); 31P NMR (121.5 MHz, 
CDCl3) δ: 22.73. Anal. Calcd. for C21H26N3O6P: C, 56.37; H, 5.86; N, 9.39; found: C, 56.42; 
H, 5.88; N, 9.36 (obtained on a 93:7 mixture of trans-10c and cis-10c). 
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Diethyl 5-(5-acetamido-1,3-dioxo-2,3-dihydro-1H-benzo[de]izochinolin-2-ylmethyl)-2-
methylisoxazolidin-3-yl-3-phosphonate trans-10d 
Yellow amorphous solid (crystallized from chloroform/hexane) mp 166–168°C; IR (KBr, cm-
1) νmax: 3299, 2982, 1628, 1660, 1553, 1255, 1044, 973, 784; (signals of trans-10d were 
extracted from the spectra of a 93:7 mixture of trans-10d and cis-10d); 1H NMR (300 MHz, 
CDCl3) δ: 8.81 (d, 1H, J = 2.0 Hz), 8.41 (d, 1H, J = 7.1 Hz), 8.35 (br s, NH), 8.22 (d, 1H, J = 
2.0 Hz), 8.07 (d, 1H, J = 8.1 Hz), 7.67 (dd, 1H, J = 8.1, 7.1 Hz), 4.55–4.46 (m, 2H, HC5 and 
CH2N), 4.29–4.13 (m, 5H, CH2N and 2 × CH2OP), 3.17 (ddd, 1H, J = 9.5, 7.0, 2.3 Hz, HC3), 
2.91 (s, 3H, CH3N), 2.72 (dddd, 1H, J = 18.0, 12.7, 7.0, 7.0 Hz, HαC4), 2.45 (dddd, 1H, J = 
12.7, 11.9, 9.5, 7.0 Hz, HβC4), 2.30 (s, 3H, CH3C(O)), 1.34 (t, 3H, J = 7.1 Hz, CH3CH2OP), 
1.33 (t, 3H, J = 7.1 Hz, CH3CH2OP); 13C NMR (75.5 MHz, CDCl3) δ: 169.74 (s, C(O)NH), 
163.98 (s, C(O)), 163.47 (s, C(O)), 137.34, 133.80, 132.20, 129.62, 127.16, 124.42, 124.24, 
122.37, 121.80, 121.66, 75.25 (d, J = 6.2 Hz, C5), 63.93 (d, J = 169.4 Hz, C3), 63.34 (d, J = 
6.7 Hz, CH2OP), 63.03 (d, J = 7.1 Hz, CH2OP), 46.87 (br s, CH3N), 42.70 (s, CH2N), 36.27 
(s, C4), 24.69 (s, CH3C(O)), 16.78 (d, J = 5.5 Hz, CH3CH2OP), 16.71 (d, J = 5.6 Hz, 
CH3CH2OP); 31P NMR (121.5 MHz, CDCl3) δ: 22.70. Anal. Calcd. for C23H28N3O7P: C, 
56.44; H, 5.77; N, 8.59; found: C, 56.53; H, 5.64; N, 8.67 (obtained on a 93:7 mixture of 
trans-10d and cis-10d). 
 
 
Antiviral Activity Assays  
 The compounds were evaluated against different  herpesviruses, including herpes 
simplex virus type 1 (HSV-1) strain KOS, thymidine kinase-deficient (TK-) HSV-1 KOS 
strain resistant to ACV (ACVr), herpes simplex virus type 2 (HSV-2) strain G, varicella-zoster 
virus (VZV) strains Oka and YS, TK- VZV strains 07-1 and YS-R, human cytomegalovirus 
(HCMV) strains AD-169 and Davis as well as feline herpes virus (FHV), the poxvirus 
vaccinia virus (Lederle strain),  para-influenza-3 virus, reovirus-1, Sindbis virus, Coxsackie 
virus B4, Punta Toro virus, respiratory syncytial virus (RSV), feline coronovirus (FIPV) and 
influenza A virus subtypes H1N1 (A/PR/8), H3N2 (A/HK/7/87) and influenza B virus 
(B/HK/5/72) and human immune deficiency virus (5HVV-1 and HIV-2). The antiviral  
assays, other than HIV, were based on inhibition of virus-induced cytopathicity or plaque 
formation in human embryonic lung (HEL) fibroblasts, African green monkey kidney cells 
(Vero), human epithelial cervix carcinoma cells (HeLa), Crandell-Rees feline kidney cells 
(CRFK),  or Madin Darby canine kidney cells (MDCK). Confluent cell cultures in microtiter 
96-well plates were inoculated with 100 CCID50 of virus (1 CCID50 being the virus dose to 
infect 50% of the cell cultures) or with 20 plaque forming units (PFU) and the cell cultures 
were incubated in the presence of varying concentrations of the test compounds. Viral 
cytopathicity or plaque formation (VZV) was recorded as soon as it reached completion in the 
control virus-infected cell cultures that were not treated with the test compounds. Antiviral 
activity was expressed as the EC50 or compound concentration required to reduce virus-
induced cytopathicity or viral plaque formation by 50%.  
Cytotoxicity Assays  
Cytotoxicity measurements were based on the inhibition of cell growth. HEL cells were 
seeded at a rate of 5 x 103 cells/well into 96-well microtiter plates and allowed to adhere and 
proliferate for 24 h. Then, medium containing different concentrations of the test compounds 
was added. After 3 days of further incubation at 37 °C, the cell number was determined with a 
Coulter counter. The cytostatic concentration was calculated as the CC50, or the compound 
concentration required reducing cell proliferation by 50% relative to the number of cells in the 
untreated controls. CC50 values were estimated from graphic plots of the number of cells 
(percentage of control) as a function of the concentration of the test compounds. 
Alternatively, cytotoxicity of the test compounds was expressed as the minimum cytotoxic 
concentration (MCC) or the compound concentration that caused a microscopically detectable 
alteration of cell morphology. Selectivity indexes were calculated as the ratio CC50 to EC50. 
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